	Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis. World J Urol Chen S, Jiang F, Wang J, Li J, Tan W, Ren J, Zhang M, Feng D. PMID: 42207184 [PubMed - indexed for MEDLINE]
	Deep survival learning for prognosis prediction in non-metastatic castration-resistant prostate cancer. Health Informatics J Li C, Bohman J, Patil V, McShinsky R, Yong C, Burningham Z, Halwani A. PMID: 42206427 [PubMed - indexed for MEDLINE]
	Uncertain magnitude of benefit of early second-generation androgen receptor antagonist treatment in advanced prostate cancer. Oncol Rev van de Weerdt EK, Duits AJ, Samson MJ, Schnog JB. PMID: 42206285 [PubMed]
	Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses. Front Immunol Ran L, Hu G, Fan C, Teng Y, Zhao R, Li Q, Yang JM, Zhang C. PMID: 42206054 [PubMed - indexed for MEDLINE]
	Progress in the application of combined detection of urinary tumor DNA and exosomes in the classification, staging, and clinical management of bladder cancer: a review. Front Oncol Wang M, Chen J, Wang C, He Y. PMID: 42205746 [PubMed]
	Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer. Clin Transl Radiat Oncol Dornisch AM, Domingo MR, Alexander RV, Conlin CC, Do S, McKay RR, Moiseenko V, Liss MA, Liu J, Pawlicki T, Pena S, Qiao EM, Rose BS, Rupareliya R, Sandhu AP, Scholey J, Seyedin SN, Urbanic JJ, Wei LJ, Seibert TM. PMID: 42205730 [PubMed]
	Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol Open Sci Månsson M, Talala K, Auvinen A, Hugosson J. PMID: 42205115 [PubMed]
	Artificial Intelligence-Based Objective Evaluation of Nerve-Sparing Status Combined With Preserved Urethral Length Predicts Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy. Int J Urol Ando S, Del Aguila Moraga DA, Hoshina H, Kawahira H, Nakaguchi T, Fujimura T. PMID: 42205081 [PubMed - indexed for MEDLINE]
	Retrospective analysis of adaptation frequencies and factors in offline in offline adaptive proton therapy. J Appl Clin Med Phys Pak F, Zhang H, Hao Y, Schmidt M, Liu W, Schiff J, Laugeman E, Watts M, Perkins S, Zhao T. PMID: 42204770 [PubMed - indexed for MEDLINE]
	Strategies for enhancing delivery efficiency on MR-Linac: A dosimetric study and historical plan review. J Appl Clin Med Phys Zhang Y, Tang S, Kabat C, Visak J, Chiu T, Li R, Jiang S, Lin MH. PMID: 42204767 [PubMed - indexed for MEDLINE]
	Machine learning-based prognostic model integrating preoperative HALP score and lactate dehydrogenase for predicting postoperative recurrence of prostate cancer. World J Surg Oncol Wang H, Qiu X, Li Z, Wu J, Gan L, Xie D, Wei Y, Wang J, Wang W. PMID: 42204546 [PubMed - as supplied by publisher]
	Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world study. Int J Clin Oncol Tobe T, Teishima J, Mita Y, Ueki H, Shiraishi Y, Wakita N, Okamura Y, Bando Y, Suzuki K, Hara T, Terakawa T, Chiba K, Yao A, Miyake H. PMID: 42204034 [PubMed - as supplied by publisher]
	Comparative analysis of genitourinary toxicity following bladder outlet obstruction procedures in patients before versus after radiotherapy for localized prostate cancer: a retrospective cohort study using the TriNetX database. Prostate Cancer Prostatic Dis Titus RS, Su J, Riveros C, Chen A, Shah HN, Satkunasivam R, Omidele O, Gonzalez RR. PMID: 42203958 [PubMed - as supplied by publisher]
	Optimizing the clinical management of prostate cancer in Taiwan: A multidisciplinary consensus. J Formos Med Assoc Shih-Chieh Chueh J, Cha TL, Hsueh FJ, Chen SC, Lin KJ, You BW, Zhao XJ, Yang JF, Li WI, Tsai CW, Hsu CY, Chang CH, Chen F, Said P, McMahon A. PMID: 42203621 [PubMed - as supplied by publisher]
	Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-GuÃ©rin Plus Mitomycin Versus Bacillus Calmette-GuÃ©rin Alone for Bacillus Calmette GuÃ©rin-naÃ¯ve Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.009. Eur Urol Focus Hayne D, Zhang AY, Thomas H, Redfern AD, Davis ID, Stockler MR. PMID: 42203610 [PubMed - as supplied by publisher]
	Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-GuÃ©rin Plus Mitomycin Versus Bacillus Calmette-GuÃ©rin Alone for Bacillus Calmette-GuÃ©rin-naÃ¯ve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.01.009. Eur Urol Focus Liu T, Zhu C, Yan Z. PMID: 42203609 [PubMed - as supplied by publisher]
	Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort. Anticancer Res Klatte T, Hofbauer SL, Ebert J, Ecke TH. PMID: 42203344 [PubMed - indexed for MEDLINE]
	Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma. Anticancer Res Yanishi M, Nakamoto T, Yoshida T, Mishima T, Kinoshita H. PMID: 42203341 [PubMed - indexed for MEDLINE]
	Development of a Prognostic Model for Patients Aged â‰¤65 Years With Metastatic Renal Cell Carcinoma. Anticancer Res Oishi Y, Matsushita Y, Watanabe S, Watanabe K, Watanabe H, Tamura K, Motoyama D, Yanagisawa T, Mori K, Sugiyama S, Bekku K, Toyoda S, Nukaya T, Maenosono R, Komura K, Araki M, Fujita K, Takahara K, Azuma H, Inamoto T, JK-FOOT STUDY GROUP. PMID: 42203336 [PubMed - indexed for MEDLINE]
	Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review. Anticancer Res Sabbadini P, Paganoni E, Galeasso L, Depetris I, DI Maio M, Filippi R. PMID: 42203335 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 178590

Page 1 of 8930



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy